Norethindrone


Mylan Pharmaceuticals Inc.
Human Prescription Drug
NDC 0378-7272
Norethindrone is a human prescription drug labeled by 'Mylan Pharmaceuticals Inc.'. National Drug Code (NDC) number for Norethindrone is 0378-7272. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Norethindrone drug includes Norethindrone - .35 mg/1 . The currest status of Norethindrone drug is Active.

Drug Information:

Drug NDC: 0378-7272
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Norethindrone
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Norethindrone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Mylan Pharmaceuticals Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:NORETHINDRONE - .35 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 24 Jun, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 13 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA200980
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Mylan Pharmaceuticals Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:198042
748961
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:M0447349
N0000175602
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:T18F433X4S
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Progestin [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Progesterone Congeners [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Progesterone Congeners [CS]
Progestin [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0378-7272-533 POUCH in 1 CARTON (0378-7272-53) / 1 BLISTER PACK in 1 POUCH (0378-7272-85) / 28 TABLET in 1 BLISTER PACK24 Jun, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Norethindrone norethindrone norethindrone norethindrone anhydrous lactose microcrystalline cellulose d&c yellow no. 10 ethylcellulose, unspecified magnesium stearate povidone, unspecified sodium starch glycolate type a potato starch, corn talc yellow round 220

Indications and Usage:

Indications and usage 1. indications progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. table 1: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. united states. notes: method (1) % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year. typical use among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experie
nce an accidental pregnancy during the first year if they do not stop use for any other reason. estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, fertility awareness-based methods, the diaphragm, the male condom, the oral contraceptive pill, and depo-provera are taken from the 1995 national survey of family growth corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods. (2) perfect use among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. see the text for the derivation of the estimate for each method. (3) (4) no method the percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% become pregnant within 1 year. this estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within 1 year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 85 85 spermicides foams, creams, gels, vaginal suppositories, and vaginal film. 28 18 42 fertility awareness-based methods 24 47 standard days method the ovulation and twoday methods are based on evaluation of cervical mucus. the standard days method avoids intercourse on cycle days 8 through 19. the symptothermal method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day. 5 two day method 4 ovulation method 3 symptothermal 0.4 withdrawal 22 4 46 sponge 36 parous women 24 20 nulliparous women 12 9 condom without spermicides female (fc) 21 5 41 male 18 2 43 diaphragm with spermicidal cream or jelly 12 6 57 combined pill and progestin-only pill 9 0.3 67 norelgestromin and ethinyl estradiol patch 9 0.3 67 nuvaring 9 0.3 67 depo-provera 6 0.2 56 intrauterine contraceptives paragard (copper t) 0.8 0.6 78 mirena (lng) 0.2 0.2 80 implanon 0.05 0.05 84 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 emergency contraception: emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy. ella, plan b one-step and next choice are the only dedicated products specifically marketed for emergency contraception. the label for plan b one-step (one dose is 1 white pill) says to take the pill within 72 hours after unprotected intercourse. research has shown that all of the brands listed here are effective when used within 120 hours after unprotected sex. the label for next choice (one dose is 1 peach pill) says to take 1 pill within 72 hours after unprotected intercourse and another pill 12 hours later. research has shown that both pills can be taken at the same time with no decrease in efficacy or increase in side effects and that they are effective when used within 120 hours after unprotected sex. the fda has in addition declared the following 19 brands of oral contraceptives to be safe and effective for emergency contraception: ogestrel (1 dose is 2 white pills), nordette (1 dose is 4 light-orange pills), cryselle, levora, low-ogestrel, lo/ovral, or quasence (1 dose is 4 white pills), jolessa, portia, seasonale or trivora (1 dose is 4 pink pills), seasonique (1 dose is 4 light-blue-green pills), enpresse (one dose is 4 orange pills), lessina (1 dose is 5 pink pills), aviane or loseasonique (one dose is 5 orange pills), lutera or sronyx (one dose is 5 white pills), and lybrel (one dose is 6 yellow pills). (see chapter 6.). lactational amenorrhea method: lam is a highly effective, temporary method of contraception. however, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. (see chapter 18.) source: trussell j. contraceptive efficacy. in hatcher ra, trussell j, nelson al, cates w, kowal d, policar m. contraceptive techology: twentieth revised edition. new york ny: ardent media, 2011. norethindrone tablets have not been studied for and are not indicated for use in emergency contraception.

Warnings:

Warnings cigarette smoking increases the risk of serious cardiovascular disease. women who use oral contraceptives should be strongly advised not to smoke. norethindrone tablets do not contain estrogen and, therefore, this insert does not discuss the serious health risks that have been associated with the estrogen component of combined oral contraceptives (cocs). the healthcare professional is referred to the prescribing information of combined oral contraceptives for a discussion of those risks. the relationship between progestin-only oral contraceptives and these risks is not fully defined. the healthcare professional should remain alert to the earliest manifestation of symptoms of any serious disease and discontinue oral contraceptive therapy when appropriate. 1. ectopic pregnancy the incidence of ectopic pregnancies for progestin-only oral contraceptive users is 5 per 1000 woman-years. up to 10% of pregnancies reported in clinical studies of progestin-only oral contraceptive users
are extrauterine. although symptoms of ectopic pregnancy should be watched for, a history of ectopic pregnancy need not be considered a contraindication to use of this contraceptive method. healthcare professionals should be alert to the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain while on progestin-only oral contraceptives. 2. delayed follicular atresia/ovarian cysts if follicular development occurs, atresia of the follicle is sometimes delayed and the follicle may continue to grow beyond the size it would attain in a normal cycle. generally these enlarged follicles disappear spontaneously. often they are asymptomatic; in some cases they are associated with mild abdominal pain. rarely they may twist or rupture, requiring surgical intervention. 3. irregular genital bleeding irregular menstrual patterns are common among women using progestin-only oral contraceptives. if genital bleeding is suggestive of infection, malignancy or other abnormal conditions, such nonpharmacologic causes should be ruled out. if prolonged amenorrhea occurs, the possibility of pregnancy should be evaluated. 4. carcinoma of the breast and reproductive organs some epidemiological studies of oral contraceptive users have reported an increased relative risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. these studies have predominantly involved combined oral contraceptives and there is insufficient data to determine whether the use of pops similarly increases the risk. a meta-analysis of 54 studies found a small increase in the frequency of having breast cancer diagnosed for women who were currently using combined oral contraceptives or had used them within the past ten years. this increase in the frequency of breast cancer diagnosis, within ten years of stopping use, was generally accounted for by cancers localized to the breast. there was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of use. women with breast cancer should not use oral contraceptives because the role of female hormones in breast cancer has not been fully determined. some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women. however, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. there is insufficient data to determine whether the use of pops increases the risk of developing cervical intraepithelial neoplasia. 5. hepatic neoplasia benign hepatic adenomas are associated with combined oral contraceptive use, although the incidence of benign tumors is rare in the united states. rupture of benign, hepatic adenomas may cause death through intra-abdominal hemorrhage. studies have shown an increased risk of developing hepatocellular carcinoma in combined oral contraceptive users. however, these cancers are rare in the u.s. there is insufficient data to determine whether pops increase the risk of developing hepatic neoplasia.

Dosage and Administration:

Dosage and administration to achieve maximum contraceptive effectiveness, norethindrone tablets must be taken exactly as directed. one tablet is taken every day, at the same time. administration is continuous, with no interruption between pill packs. see detailed patient labeling for detailed instruction.

Contraindications:

Contraindications progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: • known or suspected pregnancy • known or suspected carcinoma of the breast • undiagnosed abnormal genital bleeding • hypersensitivity to any component of this product • benign or malignant liver tumors • acute liver disease

Adverse Reactions:

Adverse reactions adverse reactions reported with the use of pops include: • menstrual irregularity is the most frequently reported side effect. • frequent and irregular bleeding are common, while long duration of bleeding episodes and amenorrhea are less likely. • headache, breast tenderness, nausea, and dizziness are increased among progestin-only oral contraceptive users in some studies. • androgenic side effects such as acne, hirsutism, and weight gain occur rarely. the following adverse reactions were also reported in clinical trials or during post-marketing experience: gastrointestinal disorders: vomiting, abdominal pain; general disorders and administration site conditions: fatigue, edema; psychiatric disorders: depression, nervousness; musculoskeletal and connective tissue disorders: pain in extremity; reproductive system and breast disorders: genital discharge; breast pain, menstruation delayed, suppressed lactation, vaginal hemorrhage, menorrhagia, withdra
wal bleed when product is stopped; immune system disorders: anaphylactic/anaphylactoid reaction, hypersensitivity ; hepatobiliary disorders: hepatitis, jaundice cholestatic; skin and subcutaneous tissue disorders: alopecia, rash, rash pruritic.

Overdosage:

Overdosage there have been no reports of serious ill effects from overdosage, including ingestion by children.

Description:

Description norethindrone tablets, usp each tablet contains 0.35 mg norethindrone. inactive ingredients include corn starch, d&c yellow no. 10, ethyl cellulose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate and talc. meets usp dissolution test 2 structure

Clinical Pharmacology:

Clinical pharmacology 1. mode of action norethindrone tablets progestin-only oral contraceptives prevent conception by suppressing ovulation in approximately half of users, thickening the cervical mucus to inhibit sperm penetration, lowering the midcycle lh and fsh peaks, slowing the movement of the ovum through the fallopian tubes, and altering the endometrium. 2. pharmacokinetics serum progestin levels peak about two hours after oral administration, followed by rapid distribution and elimination. by 24 hours after drug ingestion, serum levels are near baseline, making efficacy dependent upon rigid adherence to the dosing schedule. there are large variations in serum levels among individual users. progestin-only administration results in lower steady-state serum progestin levels and a shorter elimination half-life than concomitant administration with estrogens.

How Supplied:

How supplied norethindrone tablets usp, 0.35 mg are available in a blister pack containing 28 yellow, round, flat faced, beveled edge tablets, debossed 220 on one side and other side plain. carton of 3 tri-laminated aluminium pouches (ndc 0378-7272-53), each pouch contains one blister pack of 28 tablets. store at 20° to 25°c (68° to 77°f). [see usp controlled room temperature.] keep this and all medications out of the reach of children. reference 1. mccann m, and potter l. progestin-only oral contraceptives: a comprehensive review. contraception, 50:60 (suppl. 1), december 1994. 2. van giersbergen plm, halabi a, dingemanse j. pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. int j clin pharmacol ther 2006;44(3):113-118. 3. truitt st, fraser a, gallo me, lopez lm, grimes da and schulz kf. combined hormonal versus nonhormonal versus progestin-only contraception in lactation (review). the cochrane collaboration. 2007
, issue 3. 4. halderman, ld and nelson al. impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. am j obstet gynecol.; 186 (6): 1250-1258. 5. ostrea em, mantaring iii jb, silvestre ma. drugs that affect the fetus and newborn infant via the placenta or breast milk. pediatr clin n am; 51(2004): 539-579. 6. cooke id, back dj, shroff ne: norethisterone concentration in breast milk and infant and maternal plasma during ethynodiol diactetate administration. contraception 1985; 31:611-21. 7. 2008 uspc official:12/1/08-4/30/09, usp monographs: norethindrone tablets (page 1 of 5).

Spl Patient Package Insert:

Detailed patient labeling norethindrone tablets, usp this product (like all oral contraceptives) is used to prevent pregnancy. it does not protect against hiv infection (aids) or other sexually transmitted diseases. description norethindrone tablets, usp each tablet contains 0.35 mg norethindrone. inactive ingredients include corn starch, d&c yellow no. 10, ethyl cellulose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate and talc. introduction this leaflet is about birth control pills that contain one hormone, a progestin. please read this leaflet before you begin to take your pills. it is meant to be used along with talking with your healthcare professional. progestin-only pills are often called "pops" or "the minipill." pops have less progestin than the combined birth control pill (or "the pill") which contains both an estrogen and a progestin. how effective are pops? about 1 in 200 pop users will get pregnant in the first year if
they all take pops perfectly (that is, on time, every day). about 1 in 20 "typical" pop users (including women who are late taking pills or miss pills) gets pregnant in the first year of use. table 2 will help you compare the efficacy of different methods. table 2: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. united states. notes: method (1) % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year. typical use among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, fertility awareness-based methods, the diaphragm, the male condom, the oral contraceptive pill, and depo-provera are taken from the 1995 national survey of family growth corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods. (2) perfect use among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. see the text for the derivation of the estimate for each method. (3) (4) no method the percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% become pregnant within 1 year. this estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within 1 year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 85 85 spermicides foams, creams, gels, vaginal suppositories, and vaginal film. 28 18 42 fertility awareness-based methods 24 47 standard days method the ovulation and twoday methods are based on evaluation of cervical mucus. the standard days method avoids intercourse on cycle days 8 through 19. the symptothermal method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day. 5 two day method 4 ovulation method 3 symptothermal 0.4 withdrawal 22 4 46 sponge 36 parous women 24 20 nulliparous women 12 9 condom without spermicides female (fc) 21 5 41 male 18 2 43 diaphragm with spermicidal cream or jelly 12 6 57 combined pill and progestin-only pill 9 0.3 67 norelgestromin and ethinyl estradiol patch 9 0.3 67 nuvaring 9 0.3 67 depo-provera 6 0.2 56 intrauterine contraceptives paragard (copper t) 0.8 0.6 78 mirena (lng) 0.2 0.2 80 implanon 0.05 0.05 84 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 emergency contraception: emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy. ella, plan b one-step and next choice are the only dedicated products specifically marketed for emergency contraception. the label for plan b one-step (one dose is 1 white pill) says to take the pill within 72 hours after unprotected intercourse. research has shown that all of the brands listed here are effective when used within 120 hours after unprotected sex. the label for next choice (one dose is 1 peach pill) says to take 1 pill within 72 hours after unprotected intercourse and another pill 12 hours later. research has shown that both pills can be taken at the same time with no decrease in efficacy or increase in side effects and that they are effective when used within 120 hours after unprotected sex. the fda has in addition declared the following 19 brands of oral contraceptives to be safe and effective for emergency contraception: ogestrel (1 dose is 2 white pills), nordette (1 dose is 4 light-orange pills), cryselle, levora, low-ogestrel, lo/ovral, or quasence (1 dose is 4 white pills), jolessa, portia, seasonale or trivora (1 dose is 4 pink pills), seasonique (1 dose is 4 light-blue-green pills), enpresse (one dose is 4 orange pills), lessina (1 dose is 5 pink pills), aviane or loseasonique (one dose is 5 orange pills), lutera or sronyx (one dose is 5 white pills), and lybrel (one dose is 6 yellow pills). (see chapter 6.). lactational amenorrhea method: lam is a highly effective, temporary method of contraception. however, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. (see chapter 18.) source: trussell j. contraceptive efficacy. in hatcher ra, trussell j, nelson al, cates w, kowal d, policar m. contraceptive techology: twentieth revised edition. new york ny: ardent media, 2011. norethindrone tablets have not been studied for and are not indicated for use in emergency contraception. how do pops work? pops can prevent pregnancy in different ways including: • they make the cervical mucus at the entrance to the womb (the uterus) too thick for the sperm to get through to the egg. • they prevent ovulation (release of the egg from the ovary) in about half of the cycles. • they also affect other hormones, the fallopian tubes and the lining of the uterus. you should not take pops • if there is any chance you may be pregnant. • if you have breast cancer. • if you have bleeding between your periods that has not been diagnosed. • if you are hypersensitive, or allergic, to any component of this product. • if you have liver tumors, either benign or cancerous. • if you have acute liver disease. risks of taking pops cigarette smoking greatly increases the possibility of suffering heart attacks and strokes. women who use oral contraceptives are strongly advised not to smoke. warning: if you have sudden or severe pain in your lower abdomen or stomach area, you may have an ectopic pregnancy or an ovarian cyst. if this happens, you should contact your healthcare professional immediately. ectopic pregnancy an ectopic pregnancy is a pregnancy outside the womb. because pops protect against pregnancy, the chance of having a pregnancy outside the womb is very low. if you do get pregnant while taking pops, you have a slightly higher chance that the pregnancy will be ectopic than do users of some other birth control methods. ovarian cysts these cysts are small sacs of fluid in the ovary. they are more common among pop users than among users of most other birth control methods. they usually disappear without treatment and rarely cause problems. cancer of the reproductive organs and breasts some studies in women who use combined oral contraceptives that contain both estrogen and a progestin have reported an increase in the risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. there is insufficient data to determine whether the use of pops similarly increases this risk. a meta-analysis of 54 studies found a small increase in the frequency of having breast cancer diagnosed for women who were currently using combined oral contraceptives or had used them within the past ten years. this increase in the frequency of breast cancer diagnosis, within ten years of stopping use, was generally accounted for by cancers localized to the breast. there was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of use. some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. however, this finding may be related to factors other than the use of oral contraceptives and there is insufficient data to determine whether the use of pops increases the risk of developing cancer of the cervix. liver tumors in rare cases, combined oral contraceptives can cause benign but dangerous liver tumors. these benign liver tumors can rupture and cause fatal internal bleeding. in addition, some studies report an increased risk of developing liver cancer among women who use combined oral contraceptives. however, liver cancers are rare. there is insufficient data to determine whether pops increase the risk of liver tumors. diabetic women diabetic women taking pops do not generally require changes in the amount of insulin they are taking. however, your healthcare professional may monitor you more closely under these conditions. sexually transmitted diseases (stds) warning: pops do not protect against getting or giving someone hiv (aids) or any other std, such as chlamydia, gonorrhea, genital warts or herpes. side effects irregular bleeding: the most common side effect of pops is a change in menstrual bleeding. your periods may be either early or late, and you may have some spotting between periods. taking pills late or missing pills can result in some spotting or bleeding. other side effects: less common side effects include headaches, tender breasts, nausea, vomiting, dizziness, and fatigue. depression, nervousness, leg pain, vaginal discharge, fluid retention, allergic reactions, jaundice or a yellowing of the skin or eyeballs, loss of scalp hair, rash/itchy rash, weight gain, acne and extra hair on your face and body have been reported, but are rare. if you are concerned about any of these side effects, check with your healthcare professional. using pops with other medicines before taking a pop, inform your healthcare professional of any other medication, including over-the-counter medicine, that you may be taking. these medicines can make pops less effective: medicines for seizures such as: • phenytoin • carbamazepine • phenobarbital • felbamate • oxcarbazepine • rufinamide medicine for nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines: • (fos)aprepitant medicines for tuberculosis (tb): • rifampin and rifabutin medicine for fungal infections such as: • griseofulvin medicine for pulmonary hypertension such as: • bosentan medicines used for the treatment of hiv infections or aids and infections due to hepatitis c such as: • efavirenz, nevirapine, nelfinavir, and some ritonavir-containing drugs herbal products such as: • st. john’s wort these medicines and substances can increase your exposure to pops: grapefruit juice medicines for fungal infections such as: • itraconazole • voriconazole • fluconazole • ketoconazole before you begin taking any new medicines be sure your healthcare professional knows you are taking a progestin-only birth control pill. how to take pops important points to remember • pops must be taken at the same time every day, so choose a time and then take the pill at that same time every day. every time you take a pill late, and especially if you miss a pill, you are more likely to get pregnant. • start the next pack the day after the last pack is finished. there is no break between packs. always have your next pack of pills ready. • you may have some menstrual spotting between periods. do not stop taking your pills if this happens. • if you vomit soon after taking a pill, use a backup method (such as a condom and/or a spermicide) for 48 hours. • if you want to stop taking pops, you can do so at any time, but, if you remain sexually active and don't wish to become pregnant, be certain to use another birth control method. • if you are not sure about how to take pops, ask your healthcare professional. starting pops • it's best to take your first pop on the first day of your menstrual period. • if you decide to take your first pop on another day, use a backup method (such as a condom and/or a spermicide) every time you have sex during the next 48 hours. • if you have had a miscarriage or an abortion, you can start pops the next day. if you are late or miss taking your pops ● if you are more than 3 hours late or you miss one or more pops: 1. take a missed pill as soon as you remember that you missed it, 2. then go back to taking pops at your regular time, 3. but be sure to use a backup method (such as a condom and/or a spermicide) every time you have sex for the next 48 hours. ● if you are not sure what to do about the pills you have missed, keep taking pops and use a backup method until you can talk to your healthcare professional. if you are breastfeeding • if you are fully breastfeeding (not giving your baby any food or formula), you may start your pills 6 weeks after delivery. • if you are partially breastfeeding (giving your baby some food or formula), you should start taking pills by 3 weeks after delivery. if you are switching pills • if you are switching from the combined pills to pops, take the first pop the day after you finish the last active combined pill. do not take any of the 7 inactive pills from the combined pill pack. you should know that many women have irregular periods after switching to pops, but this is normal and to be expected. • if you are switching from pops to the combined pills, take the first active combined pill on the first day of your period, even if your pops pack is not finished. • if you switch to another brand of pops, start the new brand anytime. • if you are breastfeeding, you can switch to another method of birth control at any time, except do not switch to the combined pills until you stop breastfeeding or at least until 6 months after delivery. pregnancy while on the pill if you think you are pregnant, contact your healthcare professional. even though research has shown that pops do not cause harm to the unborn baby, it is always best not to take any drugs or medicines that you don't need when you are pregnant. you should get a pregnancy test: • if your period is late and you took one or more pills late or missed taking them and had sex without a backup method. • anytime it has been more than 45 days since the beginning of your last period. will pops affect your ability to get pregnant later? if you want to become pregnant, simply stop taking pops. pops will not delay your ability to get pregnant. breastfeeding if you are breastfeeding, pops will not affect the quality or amount of your breast milk or the health of your nursing baby. however, isolated cases of decreased milk production have been reported. overdose no serious problems have been reported when many pills were taken by accident, even by a small child, so there is usually no reason to treat an overdose. other questions or concerns if you have any questions or concerns, check with your healthcare professional. you can also ask for the more detailed "professional labeling" written for doctors and other healthcare professionals. how to store your pops store at 20° to 25°c (68° to 77°f). [see usp controlled room temperature.] keep this and all medications out of the reach of children.

Package Label Principal Display Panel:

Package label.principal display panel ndc 0378-7272-53 rx only norethindrone tablets, usp 0.35 mg this product (like all oral contraceptives) is used to prevent pregnancy. it does not protect against hiv infection (aids) or other sexually transmitted diseases. an oral contraceptive 28-day regimen 3 pouches each containing 28 tablets 3s carton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.